カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場2022年：投与量別、0.5mlパッケージ、1mlパッケージ、2mlパッケージ、その他、接種材料種類別、初回ワクチン接種、再ワクチン接種

◆英語タイトル：Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22MY8990）◆商品コード：GIR22MY8990
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2022年5月（※2025年版があります。お問い合わせください。）
◆ページ数：74
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・投与量別、0.5mlパッケージ、1mlパッケージ、2mlパッケージ、その他、接種材料種類別、初回ワクチン接種、再ワクチン接種

用途別セグメントは次のように区分されます。
・0〜5歳、5〜18歳、18〜45歳、45〜65歳、65歳以上

世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場の主要な市場プレーヤーは以下のとおりです。
・Vakzine Projekt Management (VPM)、Serum Institute of India

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）メーカーの企業概要、2019年～2022年までの新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の産業チェーンを掲載しています。
・第13、14、15章では、新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Vakzine Projekt Management (VPM)、Serum Institute of India
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：投与量別、0.5mlパッケージ、1mlパッケージ、2mlパッケージ、その他、接種材料種類別、初回ワクチン接種、再ワクチン接種
・用途別分析2017年-2028年：0〜5歳、5〜18歳、18〜45歳、45〜65歳、65歳以上
・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. 0-5 Years Old accounting for % of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 0.5ml Package segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 include Vakzine Projekt Management (VPM), Serum Institute of India, , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Market segment by Application can be divided into
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
The key market players for global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market are listed below:
Vakzine Projekt Management (VPM)
Serum Institute of India
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, with price, sales, revenue and global market share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 from 2019 to 2022.
Chapter 3, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.
Chapter 13, 14, and 15, to describe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 0.5ml Package
1.2.3 1ml Package
1.2.4 2ml Package
1.2.5 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 0-5 Years Old
1.3.3 5-18 Years Old
1.3.4 18-45 Years Old
1.3.5 45-65 Years Old
1.3.6 ≥65 Years Old
1.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size & Forecast
1.4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Value (2017 & 2021 & 2028)
1.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume (2017-2028)
1.4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (2017-2028)
1.5 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity Analysis
1.5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Total Production Capacity (2017-2028)
1.5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers
1.6.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints
1.6.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Trends Analysis
2 Manufacturers Profiles
2.1 Vakzine Projekt Management (VPM)
2.1.1 Vakzine Projekt Management (VPM) Details
2.1.2 Vakzine Projekt Management (VPM) Major Business
2.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product and Services
2.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Serum Institute of India
2.2.1 Serum Institute of India Details
2.2.2 Serum Institute of India Major Business
2.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product and Services
2.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Breakdown Data by Manufacturer
3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
3.4 Market Concentration Rate
3.4.1 Top 3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturer Market Share in 2021
3.4.2 Top 6 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturer Market Share in 2021
3.5 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region
4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Region (2017-2028)
4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2028)
4.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.4 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.5 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.6 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
5 Market Segment by Type
5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Type (2017-2028)
5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2028)
5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Application (2017-2028)
6.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2028)
6.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
7.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
7.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
7.3.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
7.3.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
8.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
8.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
8.3.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
8.3.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
9.2 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
9.3 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region
9.3.1 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
10.2 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
10.3 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
10.3.1 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
10.3.2 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
11.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
11.3 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
11.3.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 and Key Manufacturers
12.2 Manufacturing Costs Percentage of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
12.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Process
12.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Typical Distributors
13.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Vakzine Projekt Management (VPM) Basic Information, Manufacturing Base and Competitors
Table 4. Vakzine Projekt Management (VPM) Major Business
Table 5. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product and Services
Table 6. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 8. Serum Institute of India Major Business
Table 9. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product and Services
Table 10. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 12. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 13. Market Position of Manufacturers in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity by Company, (K Doses): 2020 VS 2021
Table 15. Head Office and VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Site of Key Manufacturer
Table 16. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 New Entrant and Capacity Expansion Plans
Table 17. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Mergers & Acquisitions in the Past Five Years
Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) & (K Doses)
Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2023-2028) & (K Doses)
Table 20. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) & (USD Million)
Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2023-2028) & (USD Million)
Table 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses)
Table 23. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses)
Table 24. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (USD Million)
Table 25. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2023-2028) & (USD Million)
Table 26. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2022) & (USD/Dose)
Table 27. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2023-2028) & (USD/Dose)
Table 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses)
Table 29. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses)
Table 30. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (USD Million)
Table 31. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2023-2028) & (USD Million)
Table 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2022) & (USD/Dose)
Table 33. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2023-2028) & (USD/Dose)
Table 34. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses)
Table 35. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2023-2028) & (K Doses)
Table 36. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (USD Million)
Table 37. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2023-2028) & (USD Million)
Table 38. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses)
Table 39. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses)
Table 40. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses)
Table 41. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses)
Table 42. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses)
Table 43. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2023-2028) & (K Doses)
Table 44. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (USD Million)
Table 45. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2023-2028) & (USD Million)
Table 46. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses)
Table 47. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses)
Table 48. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses)
Table 49. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses)
Table 50. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) & (K Doses)
Table 51. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2023-2028) & (K Doses)
Table 52. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) & (USD Million)
Table 53. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2023-2028) & (USD Million)
Table 54. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses)
Table 55. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses)
Table 56. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses)
Table 57. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses)
Table 58. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses)
Table 59. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2023-2028) & (K Doses)
Table 60. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (USD Million)
Table 61. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2023-2028) & (USD Million)
Table 62. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses)
Table 63. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses)
Table 64. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses)
Table 65. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses)
Table 66. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) & (K Doses)
Table 67. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2023-2028) & (K Doses)
Table 68. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) & (USD Million)
Table 69. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2023-2028) & (USD Million)
Table 70. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses)
Table 71. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses)
Table 72. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses)
Table 73. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses)
Table 74. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Raw Material
Table 75. Key Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Raw Materials
Table 76. Direct Channel Pros & Cons
Table 77. Indirect Channel Pros & Cons
Table 78. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Typical Distributors
Table 79. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Typical Customers
List of Figures
Figure 1. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Picture
Figure 2. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type in 2021
Figure 3. 0.5ml Package
Figure 4. 1ml Package
Figure 5. 2ml Package
Figure 6. Other
Figure 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application in 2021
Figure 8. 0-5 Years Old
Figure 9. 5-18 Years Old
Figure 10. 18-45 Years Old
Figure 11. 45-65 Years Old
Figure 12. ≥65 Years Old
Figure 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (2017-2028) & (K Doses)
Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (2017-2028) & (USD/Dose)
Figure 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity (2017-2028) & (K Doses)
Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers
Figure 20. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints
Figure 21. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Trends
Figure 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Manufacturer in 2021
Figure 23. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Manufacturer in 2021
Figure 24. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturer (Revenue) Market Share in 2021
Figure 27. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2028)
Figure 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2017-2028)
Figure 29. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (USD Million)
Figure 30. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (USD Million)
Figure 32. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (USD Million)
Figure 34. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028)
Figure 35. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028)
Figure 36. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2028) & (USD/Dose)
Figure 37. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028)
Figure 38. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028)
Figure 39. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2028) & (USD/Dose)
Figure 40. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028)
Figure 41. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028)
Figure 42. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2017-2028)
Figure 43. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2017-2028)
Figure 44. United States VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028)
Figure 48. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028)
Figure 49. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2017-2028)
Figure 50. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2017-2028)
Figure 51. Germany VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2017-2028)
Figure 60. China VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028)
Figure 67. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028)
Figure 68. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Country (2017-2028)
Figure 69. South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Country (2017-2028)
Figure 70. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2017-2028)
Figure 76. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in 2021
Figure 81. Manufacturing Process Analysis of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
Figure 82. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場2022年：投与量別、0.5mlパッケージ、1mlパッケージ、2mlパッケージ、その他、接種材料種類別、初回ワクチン接種、再ワクチン接種(Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 経口新型コロナウイルス感染症ワクチンのグローバル市場予測2023-2029
  • mRNA新型コロナウイルスワクチンのグローバル市場予測2023-2029
  • 潜在性結核感染検出の世界市場2022年～2029年：検査別、エンドユーザー別、地域別
  • 世界の集中治療室機器（新型コロナウイルス感染症）市場2022年：侵襲的人工呼吸器、非侵襲的人工呼吸器、ECMO装置、独立吸引器、その他
  • 世界のレムデシビル（新型コロナウイルス感染症）市場2022年：5mg、10mg、50mg、100mg